Aerosol Therapy in Obese COPD Patients.

NACompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

December 2, 2017

Primary Completion Date

April 3, 2018

Study Completion Date

May 5, 2018

Conditions
Chronic Obstructive Pulmonary Disease ModerateObesity
Interventions
RADIATION

inhalation protocol

technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution

DEVICE

High Flow Nasal Cannula

aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). A High Flow Nasal Cannula will deliver the aerosol at a 30L/min flow of oxigen.

Trial Locations (1)

50670-901

Universidade Federal de Pernambuco, Recife

All Listed Sponsors
lead

Universidade Federal do Rio Grande do Norte

OTHER

NCT03031093 - Aerosol Therapy in Obese COPD Patients. | Biotech Hunter | Biotech Hunter